Efficacy and safety of Duloxetine compared with placebo for diabetic neuropathy pain: meta-analysis.

Simple item page
dc.contributor.authorHassan, M A
dc.contributor.authorCheng, X Y
dc.contributor.authorDai, Z
dc.contributor.authorRahmathullah, M N
dc.contributor.authorShahnawaz
dc.contributor.authorShamsa, H
dc.contributor.authorFathuma, H
dc.contributor.authorHussein, A H
dc.date.accessioned2016-11-07T05:45:26Z
dc.date.available2016-11-07T05:45:26Z
dc.date.issued2016-07
dc.description.abstractBackground: Duloxetine is relatively considered as a treatment for diabetic neuropathy pain due it is balanced and potent reuptake inhibitor of both serotonin and nor epinephrine where these neurotransmitters play a great in pain inhibition. Materials and Methods: We searched DLX related articles in Pubmed, Cochrane and Embase from 2005 to 2010. 158 articles were found after through search out of which 68 articles were case reports, reviews and meta-analysis, 40 studies were clinical trials but not efficient data was available, 45 studies were RCTs but not related to our topic. Only 5 RCTs included after exclusion. We then performed the meta-analysis of the studies which met our eligibility criteria we performed fixed effect model network meta-analysis to analyze the efficacy of DLX compare to placebo. We chose diabetic neuropathy duration, diabetes mellitus duration, types of diabetes and DLX with regard to MNSI scale. Results: 5 published RCTs were included in this meta-analysis no significant difference observed for DLX and DND [(SD mean difference 0.22 (95%CI -0.16 to 0.60); P=0.25)] , on diabetes mellitus duration for HbA1c and fasting blood glucose (FBG) [(SD mean difference -0.00 (95%CI-0.087 to 0.87); P=1.00)] and on types of diabetes[(COR 1.00 (95% CI 0.73 to 1.38; P=0.98)] and [(OR 1.00 (95% CI 0.72 to 1.37); P=0.98)] .DLX shown to have significant efficacious compared to placebo for MNSI (95% CI -0.37 to – 0.03); P=0.02)]. Conclusion: In the fixed effect model analyses of DLX, showed similar efficacy to placebo for efficacy parameters, except on MNSI scale but not clinically relevant.en_US
dc.identifier.citationHassan M A, Cheng X Y, Dai Z, Rahmathullah M N, Shahnawaz, Shamsa H, Fathuma H, Hussein A H. Efficacy and safety of Duloxetine compared with placebo for diabetic neuropathy pain: meta-analysis. International Journal of Medical and Dental Sciences. 2016 July; 5(2): 1304-1311.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/178259
dc.language.isoenen_US
dc.source.urihttps://ijmds.org/wp-content/uploads/2016/06/1304-1311-ReV-Duloxetine.pdfen_US
dc.subjectDuloxetineen_US
dc.subjectserotonin (5-HT)en_US
dc.subjectnor-epinephrineen_US
dc.subjectdiabetic neuropathyen_US
dc.subjectdiabetes mellitusen_US
dc.subjectMNSIen_US
dc.subjectMeta-analysisen_US
dc.titleEfficacy and safety of Duloxetine compared with placebo for diabetic neuropathy pain: meta-analysis.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijmds2016v5n2p1304.pdf
Size:
1.52 MB
Format:
Adobe Portable Document Format
Description:
Review article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
International Journal of Medical and Dental Sciences